ORGO Organogenesis Holdings Inc

Price (delayed)

$1.76

Market cap

$226.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

$246.57M

?
Relative Growth: Rel. Growth: 33
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 35
Relative Profitability: Rel. Profitability: 22

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s ...

Highlights
ORGO's debt has soared by 64% year-on-year but it is down by 6% since the previous quarter
The company's revenue fell by 11% QoQ but it rose by 7% YoY
ORGO's equity is down by 39% QoQ and by 36% YoY
Organogenesis Holdings's gross profit has decreased by 14% QoQ

Key stats

What are the main financial stats of ORGO

ORGO stock price

How has the Organogenesis Holdings stock price performed over time
Intraday
-2.76%
1 week
-26.97%
1 month
-22.47%
1 year
-64.15%
YTD
-66.02%
QTD
-27.57%

Financial performance

How have Organogenesis Holdings's revenue and profit performed over time
Revenue
$457.45M
Gross profit
$321.84M
Operating income
-$35.87M
Net income
-$84.16M
Gross margin
70.4%
Net margin
-18.4%
Organogenesis Holdings's operating income has plunged by 57% YoY
Organogenesis Holdings's operating margin has decreased by 47% YoY
Organogenesis Holdings's gross profit has decreased by 14% QoQ
The company's revenue fell by 11% QoQ but it rose by 7% YoY

Price vs fundamentals

How does ORGO's price correlate with its fundamentals

Growth

What is Organogenesis Holdings's growth rate over time

Valuation

What is Organogenesis Holdings stock price valuation
P/E
N/A
P/B
1.53
P/S
0.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
ORGO's equity is down by 39% QoQ and by 36% YoY
The P/B is 36% below the 5-year quarterly average of 2.4 and 19% below the last 4 quarters average of 1.9
ORGO's P/S is 58% below its 5-year quarterly average of 1.2 and 44% below its last 4 quarters average of 0.9
The company's revenue fell by 11% QoQ but it rose by 7% YoY

Efficiency

How efficient is Organogenesis Holdings business performance
The return on sales has dropped by 57% year-on-year
The return on invested capital has declined by 35% year-on-year

Dividends

What is ORGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORGO.

Financial health

How did Organogenesis Holdings financials performed over time
ORGO's total assets is down by 22% since the previous quarter and by 12% year-on-year
Organogenesis Holdings's total liabilities has increased by 18% YoY but it has decreased by 15% QoQ
ORGO's debt is 55% smaller than its equity
The debt to equity has soared by 165% year-on-year and by 55% since the previous quarter
ORGO's debt has soared by 64% year-on-year but it is down by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.